Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
iTeos Therapeutics logo — Cancer Immunotherapies by Design

iTeos Therapeutics

Cancer Immunotherapies by Design

Founded 2011 United States Cambridge, United States 186 employees Post-IPO Equity Total: $362.74M Biotechnology, Health Care

General Information

Company Name iTeos Therapeutics
Founded Year 2011
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 186
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with iTeos Therapeutics. To contact iTeos Therapeutics, visit iteostherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does iTeos Therapeutics compare?

A PDF of iTeos Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting iTeos Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About iTeos Therapeutics

iTeos Therapeutics is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Watertown, MA with a research center in Gosselies, Belgium. The company's slogan, "Cancer Immunotherapies by Design," reflects its focus on pioneering the discovery and development of a new generation of immuno-oncology therapeutics for cancer patients. Leveraging a deep understanding of tumor immunology and immunosuppressive pathways, iTeos Therapeutics designs novel product candidates targeting validated immuno-oncology pathways such as the TIGIT/CD226 axis and the adenosine pathway with optimized pharmacologic properties for improved clinical outcomes. In April 2020, iTeos Therapeutics secured a significant $125.00M Series B investment from a consortium of investors including HBM Healthcare Investments, MPM Capital, 6 Dimensions Capital, Boxer Capital, Invus, HBM Partners, RTW Investments, curative ventures, S.R.I.W., and Vives Louvain Technology Fund. This funding is a testament to the confidence these prominent investors have in the potential of iTeos Therapeutics and its innovative pipeline. With its groundbreaking approach to cancer immunotherapies, iTeos Therapeutics is poised to make a significant impact in the biotechnology and healthcare industries.

Business keywords: biopharmaceutical company, immuno-oncology, clinical-stage, tumor immunology, immunosuppressive pathways, product candidates, immune response, cancer therapy, pharmacologic properties, TIGIT/CD226 axis, adenosine pathway, research center, Watertown, Gosselies

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $120.00M 2
RA Capital Management Boxer Capital
RA Capital Management, Boxer Capital
10 May 2024
Series B $125.00M 10
HBM Healthcare Investments MPM Capital RA Capital Management
HBM Healthcare Investments, MPM Capital +8
01 Apr 2020
Grant €15.00M -
30 Jan 2020
Series B $75.00M 8
MPM Capital 6 Dimensions Capital Belgian Federal Investment
MPM Capital, 6 Dimensions Capital +6
20 Jun 2018
Grant €7.50M -
28 Jul 2017
Grant Undisclosed -
24 Oct 2016
Grant €8.30M -
21 Apr 2016
Grant €2.94M -
07 Dec 2015
Series A €9.00M 6
Belgian Federal Investment Fund+ Hunza Ventures
Belgian Federal Investment, Fund+ +4
03 May 2012

iTeos Therapeutics Alternatives & Competitors

View All Alternatives
iTeos Therapeutics vs
Elpiscience Biopharmaceuticals
Elpiscience Biopharmaceuticals China

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation canc...

Series C
32 employees
Biopharma, Biotechnology
Compare iTeos Therapeutics vs Elpiscience Biopharmaceuticals
iTeos Therapeutics vs
Surface Oncology Inc.
Surface Oncology Inc. United States

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021

Post-IPO Equity
14 employees
Biotechnology, Health Care
Compare iTeos Therapeutics vs Surface Oncology Inc.
iTeos Therapeutics vs
Apexigen
Apexigen United States

Creating Transformative Immunotherapies for Patients with Cancer

Post-IPO Equity
11 employees
Biopharma, Biotechnology
Compare iTeos Therapeutics vs Apexigen
View all alternatives

FAQ About iTeos Therapeutics

Cancer Immunotherapies by Design
iTeos Therapeutics was founded in 2011.
iTeos Therapeutics is headquartered in Cambridge, United States.
iTeos Therapeutics operates in Biotechnology and Health Care. Its work centres on biopharmaceutical company, immuno-oncology, clinical-stage and tumor immunology.
iTeos Therapeutics has approximately 186 employees.
iTeos Therapeutics has completed 9 funding rounds, raising a total of $362.74M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to iTeos Therapeutics include Elpiscience Biopharmaceuticals, Surface Oncology Inc., Apexigen, NEOGAP Therapeutics AB, HiberCell. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
iTeos Therapeutics and Elpiscience Biopharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for iTeos Therapeutics, https://bouncewatch.com/company/iteos-therapeutics, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout